PUBLISHED DATE : Oct 2019 | Pages : 290
Fill out your details & get your free sample
Healthcare-associated Infectious Disease Diagnostics Market Size, Share, Trends, Analysis Report by Products (Consumables and Diagnostic Analyzers/Instruments Devices), Infections (Urinary Tract Infections, Surgical Site Infections, Hospital-Acquired Pneumonia, Bloodstream Infections, and Other Healthcare-Associated Infections), Tests (Traditional Diagnostics and Molecular Diagnostics), End-Users (Hospitals, Clinics, Ambulatory Surgical Centers (ASCs), and Other End-Users), and Geography (North America, APAC, Europe, Latin America, and Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Trends, Competitive Landscape, Share & Forecast, 2019–2024
290 Pages
33 Tables
165 Charts
5 Regions
17 Countries
25 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| MARKET SIZE (REVENUE) | USD 5.4 Billion (2024) |
| CAGR | 8% (2019-2024) |
| Base Year | 2018 |
| Historic Year | 2013 - 2016 |
| Forecast Year | 2019 - 2024 |
| Market Segments | Products (Consumables and Diagnostic Analyzers/Instruments Devices), Infections (Urinary Tract Infections, Surgical Site Infections, Hospital-Acquired Pneumonia, Bloodstream Infections, and Other Healthcare-Associated Infections), Tests (Traditional Diagnostics and Molecular Diagnostics), End-Users (Hospitals, Clinics, Ambulatory Surgical Centers (ASCs), and Other End-Users) |
| Geographic Analysis | North America, APAC, Europe, Latin America, and Middle East & Africa |
| Countries Covered | Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa ,South Korea, Spain, Turkey, UK, and US |
The growing demand for POC tests for the diagnosis of healthcare-associated infections (HAIs) will have a positive impact on the growth of the market
The global healthcare-associated infectious disease diagnostics market size to reach USD 5.4 billion by 2024 growing at a CAGR of over 8% during the forecast period. The application of molecular diagnostics, especially for HAIs, has steadily progressed from research-based highly complex tests to widespread adoption by a diverse range of end-users. While traditional techniques are being challenged, the development of molecular diagnostic tests offers a variety of advantages such as high accuracy and specificity and perform multiple tests in a single instance. Molecular diagnostics will become a critical part of hospital-acquired infections testing, especially in the battle against antibiotic resistance. Hence, the adoption of molecular diagnostics is likely to increase at a significant rate due to its high sensitivity, specificity, and accuracy, as well as the capability to deliver results quickly. This adoption of molecular diagnostic testing will have a positive impact on the growth of the overall healthcare-associated infections diagnostics market in the coming years.
The dynamics of the healthcare sector is changing due to ongoing healthcare reforms, increasing economic expenditure, and growing recognition that healthcare services need to be less fragmented and more patient-centric. Point-of-care (POC) diagnostics testing is perceived as one of the ways to achieve patient-centric healthcare and cost-effective treatment for patients. POC tests offer significant benefits over the traditional lab-based tests for diagnosing HAIs. For instance, patients admitted in ICUs and neonates in neonatal intensive care could be benefitted as the test could be performed at the bedside, and immediate results can be obtained. Therefore, the growing demand for POC tests for the diagnosis of HAIs will have a positive impact on the growth of the market during the forecast period. The healthcare-associated infectious disease diagnostics market is expected to grow at a CAGR of over 8% during the period 2018–2024.
This research report includes detailed market segmentation by
The growing awareness of HAIs worldwide is one of the key factors fueling the growth of the consumable segment
The usage of a wide array of reagents and test kits to perform diagnostic tests for diagnosing several HAIs in healthcare settings is a major factor for the growth of the consumables segment. Also, the growing awareness of HAIs worldwide is one of the key factors fueling the growth of the consumable segment. The consumables segment is growing due to the increasing usage of several microbial culture tests, urinalysis, immunoassay tests, and PCR tests in several healthcare settings for diagnosing infectious diseases.
The analyzer segment is growing at a relatively slower pace than the consumables segment as it is capital intensive, and purchasing decisions for analyzers depend on financial resources and budget allocations. However, analyzers used in molecular diagnostic tests and at POC sites are growing at a relatively higher growth rate than clinical laboratory analyzers as end-users are preferring analyzers with high sensitivity and delivering highly accurate results with less turnaround time.
Urinary tract infections account for 35−40% of nosocomial infections and occupy the largest share in the overall HAIs category
Urinary tract infections (UTI) account for 35−40% of all nosocomial infections and occupy the largest share in the overall HAIs category. The prevalence of hospital-acquired UTIs is continuously increasing globally. Several technological advancements have enhanced the testing procedures for hospital-acquired UTIs. New diagnostic platforms have improved the accuracy and speed of pathogen identification from primary cultures. The market is likely to grow at a CAGR of 9% during the forecast period.
Surgical site infections are the most common complications following major gastrointestinal surgeries, affecting between 25 and 40% of patients. The surgical site infections (SSI) segment is growing at a steady rate and is likely to grow at a similar pace during the forecast period. SSIs remain a significant clinical challenge as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources.
The prevalence of hospital-acquired pneumonia (HAP) and related deaths is increasing at an alarming rate worldwide. Therefore, there is an increased emphasis on minimizing the occurrence of HAP in healthcare settings. The market is expected to witness fast growth in the coming years due to the development and commercialization of advanced nucleic acid detection tests and advancements in POC testing products for pneumonia. Further, the growing awareness of the benefits of a quick diagnosis of HAP is increasing the demand for HAP diagnostic tests both in developed and developing countries. The segment is expected to grow at a CAGR of over 9% during the forecast period.
The market is witnessing widespread uptake of POC diagnostic tests for the diagnosis of several infections in several healthcare settings
The traditional diagnostics segment is growing at a moderate rate. A reliable and accurate diagnosis of HAIs is of utmost importance in healthcare settings. Traditional diagnostic tests are considered as the gold-standard and are widely used to diagnose HAIs. The healthcare-associated infections diagnostics market is witnessing widespread uptake of POC diagnostic tests for the diagnosis of several infections in several healthcare settings such as acute and ambulatory healthcare settings. Therefore, there is a growing need for highly efficient and automated diagnostic tests for diagnosing HAIs, especially antibiotic-resistant microbes.
The molecular diagnostics market segment is growing at a faster rate than the traditional diagnostics segment. This growth can be attributed to multiple advantages and clinically proven superior efficacy of molecular diagnostic tests. The increasing availability of automated and compact analyzers has significantly improved the efficiency and quality of end-user operations. These automated analyzers are designed to meet the high demand for quality diagnostic testing.
Developing countries are 20 times more prone to HAIs risk than developed countries
Hospitals are the major source for HAIs, and many hospitalized patients acquire several pathogenic and non-pathogenic infections during the stay. Most hospitals report central line-associated bloodstream infections, catheter-associated UTIs, and SSIs following surgeries such as heart, abdominal hysterectomy, colon, and knee surgical procedures. The adoption of diagnostic testing for healthcare-associated infections is steadily increasing globally to tackle adverse events related to HAIs and take appropriate decisions on treatments. Therefore, the increase in the number of people with HAIs is encouraging physicians in hospitals to use advanced and rapid diagnostic tests, thereby contributing to the growth of the segment.
Healthcare-associated infections are no longer confined to hospitals. Small and medium-sized clinics, physician offices, and solo practitioners are non-adherent to recommended infection prevention and control procedures. Developing countries have reported 20 times more HAIs risk in clinics than in developed countries. The rapid emergence and prevalence of community-associated infections caused by resistant microbes has been recognized to cause serious infections among patients. Therefore, the high risk of HAIs in clinics and ASCs is expected to drive the healthcare-associated infections diagnostics market.
The increased uptake of molecular diagnostic testing for diagnosing HAIs is a key reason for the significant market growth
The healthcare-associated infections diagnostics market in North America is likely to witness upward growth in terms of revenue, with key vendors focusing on developing innovative and advanced infectious disease diagnostics products, which will offer efficient results. The US is the major revenue contributor to the global market due to the presence of health coverage and the availability of advanced health infrastructure. With the growing demand for diagnostic devices for HAIs, vendors are focusing on introducing innovative products to cater to the growing demand for advanced diagnostic techniques for HAIs in the US.
Europe accounts for the second-highest market share in the global healthcare-associated infections diagnostics market. Countries such as Germany, France, the UK, Spain, Italy, and Denmark have a high occurrence rate of HAIs. According to the European Centre for Disease Control and Prevention (ECDC), approximately 9 million HAI cases occur across Europe annually. The increased uptake of molecular diagnostic testing for diagnosing HAIs is a key reason for the significant market growth. Germany is the largest healthcare-associated infectious disease diagnostics market in Europe. The presence of a large patient pool, better accessibility to diagnostics services, and established healthcare delivery are contributing to the growth of the market in the country.
The growing demand for traditional culture-based tests and immunoassays is a major driver for the APAC market. Further, the low-cost nature and limited resource availability of performing advanced molecular tests is driving the APAC market. The frequency of ICU-acquired infections is at least 2─3 times higher in low- and middle-income countries than in high-income countries. This can be attributed to poor hygiene practices and the lack of stringent regulatory controls. Newborns are the most vulnerable population for HAIs and are at higher risk of acquiring the healthcare-associated infection in developing countries, with 3 to 20 times higher than in high-income countries.
The healthcare-associated infections diagnostics market is consolidated and is characterized by the presence of several active global, regional, and local players, offering a diverse range of diagnostic analyzers and consumables for diagnosing HAIs. Global players are focusing on developing innovative products and expanding their product portfolio to remain competitive in the market. They are investing extensively in R&D and product development activities to expand their product portfolio. Key players are also engaged in strategic acquisitions as part of the inorganic growth strategy to improve sales and profit margins. Strategic M&As continue to be an important competitive strategy for key players to expand product offerings, access new technology, or increase market share.
Market Segmentation by Products
Market Segmentation by Infections
Market Segmentation by End-users
Market Segmentation by Diagnostic Tests
Market Segmentation by Geography
Frequently Asked Questions
What is the market size and CAGR of the Healthcare-associated Infectious Disease Diagnostics Market?
Healthcare-associated infectious disease diagnostics market size to reach USD 5.4 Billion by 2024 growing at a CAGR of over 8% during the forecast period.
What factors are driving the Healthcare-associated Infectious Disease Diagnostics Market?
The growing demand for POC tests for the diagnosis of HAIs will have a positive impact on the growth of the market during the forecast period.
Abbott, Becton Dickinson, bioMérieux, Danaher, Hoffmann-La Roche, Meridian Bioscience, and QIAGEN are the leading vendors in the Healthcare-associated Infectious Disease Diagnostics Market
What is the growth of the European HAI market during the forecast period?
Europe accounts for the second-highest market share in the global healthcare-associated infections diagnostics market. Countries such as Germany, France, the UK, Spain, Italy, and Denmark have a high occurrence rate of HAIs.
What is the growth of the Urinary tract infections segment?
Urinary tract infections (UTI) account for 35−40% of all nosocomial infections and occupy the largest share in the overall HAIs category. The prevalence of hospital-acquired UTIs is continuously increasing globally.
The healthcare-associated infectious disease diagnostics market is expected to grow at a CAGR of over 8% during the period 2018–2024.
The following factors are likely to contribute to the growth of the healthcare-associated infections diagnostics market during the forecast period:
Base Year: 2018
Forecast Year: 2019–2024
The study considers the present scenario of the healthcare-associated infections diagnostics market and its market dynamics for the period 2018−2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply aspects of the market. The report profiles and examines leading companies and other prominent companies operating in the market.
Key Vendors in the Healthcare-associated Infections Diagnostics Market
Prominent Vendors in the Healthcare-associated Infections Diagnostics Market
Other Vendors in the Healthcare-associated Infectious Disease Diagnostics Market
Market Segmentation by Products
Market Segmentation by Infections
Market Segmentation by End-users
Market Segmentation by Diagnostic Tests
Market Segmentation by Geography
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of the study
4.4 Market Segments
4.4.1 Market Segmentation by Products
4.4.2 Market Segmentation by Healthcare-associated Infections
4.4.3 Market Segmentation by Diagnostic Tests
4.4.4 Market Segmentation by End-users
4.4.5 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.1.1 Causative Organisms of HAIs
7.1.2 Epidemiology of HAIs
8 Market Dynamics
8.1 Market Growth Enablers
8.1.1 Technological Advancements in Diagnostic Tools & Assays for HAIs
8.1.2 Increase in Patient Population with HAIs
8.1.3 Growing Popularity of Molecular Diagnostic Tests for HAIs
8.2 Market Growth Restraints
8.2.1 Stringent Regulations to Prevent HAIs in Healthcare Settings
8.2.2 Availability of Sophisticated Mechanisms to Control HAIs
8.2.3 Low Prevalence of HAIs in High-income Nations
8.3 Market Opportunities & Trends
8.3.1 Strategic Acquisitions
8.3.2 High Growth Potential in Low and Middle-income Countries
8.3.3 Growing Penetration of POC Tests to Diagnose HAIs
9 Market Landscape
9.1 Market Overview
9.2 Market Size & Forecast
9.3 Five Forces Analysis
9.3.1 Threat of New Entrants
9.3.2 Bargaining Power of Suppliers
9.3.3 Bargaining Power of Buyers
9.3.4 Threat of Substitutes
9.3.5 Competitive Rivalry
10 Healthcare-associated Infections Diagnostics Market by Infection Type
10.1 Market Snapshot & Growth Engine
10.2 Market Overview
10.3 Urinary Tract Infections
10.3.1 Market Overview
10.3.2 Market Size & Forecast
10.4 Surgical Site Infections
10.4.1 Market Overview
10.4.2 Market Size & Forecast
10.5 Hospital-acquired Pneumonia
10.5.1 Market Overview
10.5.2 Market Size & Forecast
10.6 BloodStream Infections
10.6.1 Market Overview
10.6.2 Market Size & Forecast
10.7 Gastrointestinal Infections
10.7.1 Market Overview
10.7.2 Market Size & Forecast
10.8 Other Healthcare-associated Infections
10.8.1 Market Overview
10.8.2 Market Size & Forecast
11 Healthcare-associated Infections Diagnostics Market by Product Type
11.1 Market Snapshot & Growth Engine
11.2 Market Overview
11.3 Consumables
11.3.1 Market Overview
11.3.2 Market Size & Forecast
11.4 Analyzers/Instruments
11.4.1 Market Overview
11.4.2 Market Size & Forecast
12 Healthcare-associated Infections Diagnostics Market by Test Type
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Traditional Diagnostics
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 Traditional Diagnostics Market Segmentation By Geography
12.4 Molecular Diagnostics
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.4.3 Molecular Diagnostics Market Segmentation by Geography
13 Healthcare-associated Infections Diagnostics Market by End-User Type
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Hospitals
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Clinics
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 ASCs
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Others
13.6.1 Market Overview
13.6.2 Market Size & Forecast
14 Healthcare-associated Infections Diagnostics Market by Geography
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
15 North America
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Market Segmentation by Test Type
15.4 Key Countries
15.4.1 US: Healthcare-associated Infections Diagnostics Market Size & Forecast
15.4.2 Canada: Market Size & Forecast
16 Europe
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Market Segmentation by Test Type
16.4 Key Countries
16.4.1 Germany: Healthcare-associated Infections Diagnostics Market Size & Forecast
16.4.2 France: Market Size & Forecast
16.4.3 UK: Healthcare-associated Infections Diagnostics Market Size & Forecast
16.4.4 Spain: Market Size & Forecast
16.4.5 Italy: Healthcare-associated Infections Diagnostics Market Size & Forecast
17 APAC
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Market Segmentation by Test Type
17.4 Key Countries
17.4.1 Japan: Healthcare-associated Infections Diagnostics Market Size & Forecast
17.4.2 China: Market Size & Forecast
17.4.3 India: Healthcare-associated Infections Diagnostics Market Size & Forecast
17.4.4 South Korea: Market Size & Forecast
17.4.5 Australia: Healthcare-associated Infections Diagnostics Market Size & Forecast
18 Latin America
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Market Segmentation by Test Type
18.4 Key Countries
18.4.1 Brazil: Healthcare-associated Infections Diagnostics Market Size & Forecast
18.4.2 Mexico: Market Size & Forecast
19 Middle-East & Africa
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Market Segmentation by Test Type
19.4 Key Countries
19.4.1 Turkey: Healthcare-associated Infections Diagnostics Market Size & Forecast
19.4.2 South Africa: Market Size & Forecast
19.4.3 Saudi Arabia: Healthcare-associated Infections Diagnostics Market Size & Forecast
20 Competitive Landscape
20.1 Competition Overview
20.2 Market Share Analysis
21 Key Company Profiles
21.1 Abbott
21.1.1 Business Overview
21.1.2 Major Product Offerings
21.1.3 Key Strengths
21.1.4 Key Strategies
21.1.5 Key Opportunities
21.2 BD
21.2.1 Business Overview
21.2.2 Major Product Offerings
21.2.3 Key Strengths
21.2.4 Key Strategies
21.2.5 Key Opportunities
21.3 bioMérieux
21.3.1 Business Overview
21.3.2 Major Product Offerings
21.3.3 Key Strengths
21.3.4 Key Strategies
21.3.5 Key Opportunities
21.4 Danaher
21.4.1 Business Overview
21.4.2 Major Product Offerings
21.4.3 Key Strengths
21.4.4 Key Strategies
21.4.5 Key Opportunities
21.5 F. Hoffmann-La Roche
21.5.1 Business Overview
21.5.2 Major Product Offerings
21.5.3 Key Strengths
21.5.4 Key Strategies
21.5.5 Key Opportunities
21.6 Meridian Bioscience
21.6.1 Business Overview
21.6.2 Major Product Offerings
21.6.3 Key Strengths
21.6.4 Key Strategies
21.6.5 Key Opportunities
21.7 QIAGEN
21.7.1 Business Overview
21.7.2 Major Product Offerings
21.7.3 Key Strengths
21.7.4 Key Strategies
21.7.5 Key Opportunities
22 Other Prominent Vendors
22.1 Trinity Biotech
22.1.1 Business Overview
22.1.2 Major Product Offerings
22.1.3 Key Strengths
22.1.4 Key Strategies
22.1.5 Key Opportunities
22.2 DiaSorin Molecular
22.2.1 Business Overview
22.2.2 Major Product Offerings
22.2.3 Key Strengths
22.2.4 Key Strategies
22.2.5 Key Opportunities
22.3 OpGen
22.3.1 Business Overview
22.3.2 Major Product Offerings
22.3.3 Key Strengths
22.3.4 Key Strategies
22.3.5 Key Opportunities
22.4 Accelerate Diagnostics
22.4.1 Business Overview
22.4.2 Major Product Offerings
22.4.3 Key Strengths
22.4.4 Key Strategies
22.4.5 Key Opportunities
22.5 Thermo Fisher Scientific
22.5.1 Business Overview
22.5.2 Major Product Offerings
22.5.3 Key Strengths
22.5.4 Key Strategies
22.5.5 Key Opportunities
22.6 Bio-Rad
22.6.1 Business Overview
22.6.2 Major Product Offerings
22.6.3 Key Strengths
22.6.4 Key Strategies
22.6.5 Key Opportunities
22.7 Luminex
22.7.1 Business Overview
22.7.2 Major Product Offerings
22.7.3 Key Strengths
22.7.4 Key Strategies
22.7.5 Key Opportunities
22.8 Quidel
22.8.1 Business Overview
22.8.2 Major Product Offerings
22.8.3 Key Strengths
22.8.4 Key Strategies
22.8.5 Key Opportunities
23 Other Vendors
23.1 Genetics Signature
23.1.1 Business Overview
23.2 Seegene
23.2.1 Business Overview
23.3 Diatherix Eurifins
23.3.1 Business Overview
23.4 Immunexpress
23.4.1 Business Overview
23.5 ResponSe Biomedical
23.5.1 Business Overview
23.6 Humor Diagnostics
23.6.1 Business Overview
23.7 Eiken Chemical
23.7.1 Business Overview
23.8 Bruker
23.8.1 Business Overview
23.9 T2 Biosystems
23.9.1 Business Overview
23.10 Hologic
23.10.1 Business Overview
24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
24.3 Quantitative Summary
24.3.1 Market by Product Type
24.3.2 Market by Test Type
24.3.3 Market by Infection Type
24.3.4 Market by End-user Type
24.3.5 Market by Geography
25 Appendix
25.1 Abbreviations
List of Exhibits
Exhibit 1 Segmentation of Global Healthcare-associated Infectious Disease Diagnostics Market
Exhibit 2 Market Size Calculation Approach 2018
Exhibit 3 Major Causes for the Spread of Healthcare-associated Infections
Exhibit 4 Technological Advancements in Diagnostic Tools & Assays for HAIs
Exhibit 5 Increase in Patient Population with HAIs
Exhibit 6 Growing Popularity of Molecular Diagnostic Tests for HAIs
Exhibit 7 Important Milestones in Molecular Diagnostics for Infectious Diseases
Exhibit 8 Comparison of Blood Culture Test Versus Molecular Diagnostic Test
Exhibit 9 Stringent Regulations to Prevent HAIs in Healthcare Settings
Exhibit 10 WHO’s Recommendations Using My 5 Moments for Hand Hygiene Approach
Exhibit 11 Important Recommendations for Healthcare Settings to Prevent HAIs
Exhibit 12 Availability of Sophisticated Mechanisms to Control HAIs
Exhibit 13 Steps Involved in Reprocessing Cycle of Sterile Supplies
Exhibit 14 Popular Equipment Used in Healthcare Settings to Control HAIs
Exhibit 15 Low Prevalence of HAIs in High-income Nations
Exhibit 16 Rate of HAIs in Europe (Per 1,000 population)
Exhibit 17 Strategic Acquisitions
Exhibit 18 High Growth Potential in Low and Middle-income Countries
Exhibit 19 Emerging Economies Witnessing Higher Absolute Growth in APAC
Exhibit 20 Emerging Economies Witnessing Higher Absolute Growth in Latin America
Exhibit 21 Growing Penetration of POC Tests to Diagnose HAIs
Exhibit 22 Global Healthcare-associated Infectious Disease Diagnostics Market 2018−2024 ($ million)
Exhibit 23 Five Forces Analysis 2018
Exhibit 24 Incremental Growth by Infection Type 2018–2024
Exhibit 25 Global Healthcare-associated Infections Diagnostics Market by Infection Type
Exhibit 26 Market by Infection Type 2018 & 2024 (%)
Exhibit 27 Market by Infection Type 2018−2024 ($ million)
Exhibit 28 Market by Infection Type 2018−2024 (%)
Exhibit 29 Market by Infection Type 2018-2024 (Incremental Growth)
Exhibit 30 Market by Infection Type 2018-2024 (Absolute Growth)
Exhibit 31 Global Healthcare-associated Infections Diagnostics Market by UTIs: Incremental and Absolute Growth Comparison
Exhibit 32 Risk Factors with Development of Hospital-associated UTIs
Exhibit 33 Market by UTIs 2018−2024 ($ million)
Exhibit 34 Hospital-acquired Bacteriuria in Patients with Indwelling Urethral Catheters (%)
Exhibit 35 Global Healthcare-associated Infections Diagnostics Market by SSIs: Incremental and Absolute Growth Comparison
Exhibit 36 Risk Factors of Surgical Site Infections
Exhibit 37 Market by SSIs 2018−2024 ($ million)
Exhibit 38 Global Healthcare-associated Infections Diagnostics Market by HAP: Incremental and Absolute Growth Comparison
Exhibit 39 Common Pathogens Causing HAP
Exhibit 40 Market by HAP 2018−2024 ($ million)
Exhibit 41 Host Risk Factors with Development of Multidrug-resistant Infection in HAP
Exhibit 42 Global Healthcare-associated Infections Diagnostics Market by BSI: Incremental and Absolute Growth Comparison
Exhibit 43 Market by BSI 2018−2024 ($ million)
Exhibit 44 Global Healthcare-associated Infections Diagnostics Market by GII: Incremental & Absolute Growth Comparison
Exhibit 45 Market by GII 2018−2024 ($ million)
Exhibit 46 Global Healthcare-associated Infections Diagnostics by Other Infections Incremental and Absolute Growth Comparison
Exhibit 47 Market by Other Infections 2018−2024 ($ million)
Exhibit 48 Incremental Growth by Product Type 2018–2024
Exhibit 49 Global Healthcare-associated Infections Diagnostics Market by Product Type
Exhibit 50 Market by Product Type 2018 & 2024 (%)
Exhibit 51 Market by Product Type 2018−2024 ($ million)
Exhibit 52 Market by Product Type 2018−2024 (%)
Exhibit 53 Market by Product Type 2018-2024 (Incremental Growth)
Exhibit 54 Market by Product Type 2018-2024 (Absolute Growth)
Exhibit 55 Global Healthcare-associated Infections Diagnostics Market by Consumables: Incremental and Absolute Growth Comparison
Exhibit 56 Market by Consumables 2018−2024 ($ million)
Exhibit 57 Global Healthcare-associated Infections Diagnostics Market by Analyzers/Instruments: Incremental and Absolute Growth Comparison
Exhibit 58 Market by Analyzers/Instruments 2018−2024 ($ million)
Exhibit 59 Incremental Growth by Test Type 2018−2024
Exhibit 60 Global Healthcare-associated Infections Diagnostics Market by Test Type
Exhibit 61 Market by Test Type 2018 & 2024 (%)
Exhibit 62 Market by Test Type 2018-2024 ($ million)
Exhibit 63 Market by Test Type 2018-2024 (%)
Exhibit 64 Market by Test Type 2018-2024 (Incremental Growth)
Exhibit 65 Market by Test Type 2018-2024 (Absolute Growth)
Exhibit 66 Global Traditional Healthcare-associated Infections Diagnostics Market: Incremental and Absolute Growth Comparison
Exhibit 67 Global Traditional HAI Diagnostics Market 2018−2024 ($ million)
Exhibit 68 Global Traditional HAI Diagnostics Market 2018 & 2024 (%)
Exhibit 69 Global Traditional HAI Diagnostics Market 2018−2024 ($ million)
Exhibit 70 Global Traditional HAI Diagnostics Market 2018−2024 (%)
Exhibit 71 Global Molecular Healthcare-associated Infections Diagnostics Market: Incremental and Absolute Growth Comparison
Exhibit 72 Major Advantages of Molecular Diagnostics
Exhibit 73 Market by Molecular Diagnostics 2018−2024 ($ million)
Exhibit 74 Global Molecular HAI Diagnostics Market 2018 & 2024 (%)
Exhibit 75 Global Molecular HAI Diagnostics Market 2018−2024 ($ million)
Exhibit 76 Global Molecular HAI Diagnostics Market 2018−2024 (%)
Exhibit 77 Incremental Growth by End-user Type 2018−2024
Exhibit 78 Global Healthcare-associated Infections Diagnostics Market by End-user Type
Exhibit 79 Market by End-user Type 2018 & 2024 (%)
Exhibit 80 Market by End-user Type 2018-2024 ($ million)
Exhibit 81 Market by End-user Type 2018-2024 (%)
Exhibit 82 Market by End-user Type 2018-2024 (Incremental Growth)
Exhibit 83 Market by End-user Type 2018-2024 (Absolute Growth)
Exhibit 84 Global Healthcare-associated Infections Diagnostics Market by Hospitals: Incremental and Absolute Growth Comparison
Exhibit 85 Market by Hospitals 2018−2024 ($ million)
Exhibit 86 Market by Clinics: Incremental and Absolute Growth Comparison
Exhibit 87 Market by Clinics 2018−2024 ($ million)
Exhibit 88 Market by ASCs: Incremental and Absolute Growth Comparison
Exhibit 89 Market by ASCs 2018−2024 ($ million)
Exhibit 90 Market by Other End-users: Incremental and Absolute Growth Comparison
Exhibit 91 Market by Other End-users 2018−2024 ($ million)
Exhibit 92 Incremental Growth by Geography 2018−2024
Exhibit 93 Global Healthcare-associated Infections Diagnostics Market by Geography
Exhibit 94 Market by Geography 2018 & 2024 (%)
Exhibit 95 Market by Geography 2018-2024 ($ million)
Exhibit 96 Market by Geography 2018-2024 (%)
Exhibit 97 Market by Geography 2018-2024 (Incremental Growth)
Exhibit 98 Market by Geography 2018-2024 (Absolute Growth)
Exhibit 99 Healthcare-associated Infections Diagnostics Market in North America: Incremental and Absolute Growth Comparison
Exhibit 100 Market in North America 2018–2024 ($ million)
Exhibit 101 North America Market by Test Type 2018 & 2024 (%)
Exhibit 102 North America Market by Test Type 2018–2024 ($ million)
Exhibit 103 North America Market by Test Type 2018–2024 (%)
Exhibit 104 Incremental Growth in North America 2018−2024
Exhibit 105 Market in US 2018–2024 ($ million)
Exhibit 106 Market in Canada 2018–2024 ($ million)
Exhibit 107 Healthcare-associated Infections Diagnostics Market in Europe: Incremental and Absolute Growth Comparison
Exhibit 108 Market in Europe 2018–2024 ($ million)
Exhibit 109 Europe Market by Test Type 2018 & 2024 (%)
Exhibit 110 Europe Market by Test Type 2018–2024 ($ million)
Exhibit 111 Europe Market by Test Type 2018–2024 (%)
Exhibit 112 Incremental Growth in Europe 2018−2024
Exhibit 113 Market in Germany 2018–2024 ($ million)
Exhibit 114 Market in France 2018–2024 ($ million)
Exhibit 115 Market in UK 2018–2024 ($ million)
Exhibit 116 Market in Spain 2018–2024 ($ million)
Exhibit 117 Market in Italy 2018–2024 ($ million)
Exhibit 118 Healthcare-associated Infections Diagnostics Market in APAC: Incremental and Absolute Growth Comparison
Exhibit 119 Market in APAC 2018–2024 ($ million)
Exhibit 120 APAC Market by Test Type 2018 & 2024 (%)
Exhibit 121 APAC Market by Test Type 2018–2024 ($ million)
Exhibit 122 APAC Market by Test Type 2018–2024 (%)
Exhibit 123 Incremental Growth in APAC 2018−2024
Exhibit 124 Market in Japan 2018–2024 ($ million)
Exhibit 125 Market in China 2018–2024 ($ million)
Exhibit 126 Market in India 2018–2024 ($ million)
Exhibit 127 Market in South Korea 2018–2024 ($ million)
Exhibit 128 Market in Australia 2018–2024 ($ million)
Exhibit 129 Healthcare-associated Infections Diagnostics Market in Latin America: Incremental and Absolute Growth Comparison
Exhibit 130 Market in Latin America 2018–2024 ($ million)
Exhibit 131 Latin America Market by Test Type 2018 & 2024 (%)
Exhibit 132 Latin America Market by Test Type 2018–2024 ($ million)
Exhibit 133 Latin America Market by Test Type 2018–2024 (%)
Exhibit 134 Incremental Growth in Latin America 2018−2024
Exhibit 135 Market in Brazil 2018–2024 ($ million)
Exhibit 136 Market in Mexico 2018–2024 ($ million)
Exhibit 137 Healthcare-associated Infections Diagnostics Market in MEA: Incremental and Absolute Growth Comparison
Exhibit 138 Market in MEA 2018–2024 ($ million)
Exhibit 139 MEA Market by Test Type 2018 & 2024 (%)
Exhibit 140 MEA Market by Test Type 2018–2024 ($ million)
Exhibit 141 MEA Market by Test Type 2018–2024 (%)
Exhibit 142 Incremental Growth in MEA 2018−2024
Exhibit 143 Market in Turkey 2018–2024 ($ million)
Exhibit 144 Market in South Africa 2018–2024 ($ million)
Exhibit 145 Market in Saudi Arabia 2018–2024 ($ million)
Exhibit 146 Global Healthcare-associated Infectious Disease Diagnostics Market: Vendors Market Shares
Exhibit 147 Abbott: R&D Expenditure 2016−2018 ($ million)
Exhibit 148 Abbott: Sales Breakdown by Segments in 2017−2018 ($ million)
Exhibit 149 Abbott: Sales Breakdown by Geography 2018 (%)
Exhibit 150 BD: R&D Expenditure 2016−2018 ($ million)
Exhibit 151 BD: Revenue by Business Segments 2017 & 2018 ($ million)
Exhibit 152 BD: Revenue Share by Geography (%)
Exhibit 153 Danaher: R&D Expenditure 2016−2018 ($ million)
Exhibit 154 Danaher: Revenue by Business Segments ($ billion)
Exhibit 155 Danaher: Percentage Share of Revenue by Geographies (%)
Exhibit 156 F. Hoffmann-La Roche: R&D Expenditure 2016−2018 ($ billion)
Exhibit 157 F. Hoffmann-La Roche: Revenue by Business Segments 2017−2018 ($ billion)
Exhibit 158 F. Hoffmann-La Roche: Revenue by Geographies (%)
Exhibit 159 Meridian Bioscience: R&D Expenditure 2016−2018 ($ million)
Exhibit 160 Meridian Bioscience: Revenue by Segments 2017−2018 ($ billion)
Exhibit 161 Meridian Bioscience: Revenue by Geography (%)
Exhibit 162 QIAGEN Revenue 2016−2018 ($ billion)
Exhibit 163 QIAGEN: R&D Expenditure 2016−2018 ($ million)
Exhibit 164 QIAGEN: Revenue by Segments 2017−2018 ($ billion)
Exhibit 165 QIAGEN: Revenue by Geographies
List of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2018
Table 3 Recent Product Approvals Related to HAI Diagnostics
Table 4 Popular Acquisitions in Hospital-acquired Infectious Disease Diagnostics Market
Table 5 Approved Diagnostic Technologies for Diagnosing Hospital-acquired UTIs
Table 6 Common Microbes Causing GI Infections
Table 7 Annual Number of Molecular Diagnostic Tests Performed for Various HAIs in 2016
Table 8 Global Healthcare-associated Infections Diagnostics Market: Vendors Ranking
Table 9 Abbott: Product Offerings
Table 10 BD: Key Product Offerings
Table 11 bioMérieux: Major Product Offerings
Table 12 Danaher: Key Product Offerings
Table 13 F. Hoffmann-La Roche: Key Product Offerings
Table 14 Meridian Bioscience: Product Offerings
Table 15 QIAGEN: Product Offerings
Table 16 Trinity Biotech: Key Product Offerings
Table 17 DiaSorin Molecular: Key Product Offerings
Table 18 OpGen: Key Product Offerings
Table 19 Accelerate Diagnostics: Key Product Offerings
Table 20 Thermo Fisher Scientific: Key Product Offerings
Table 21 Bio-Rad: Key Product Offerings
Table 22 Luminex: Key Product Offerings
Table 23 Quidel: Key Product Offerings
Table 24 Global Healthcare-associated Infections Market by Products ($ million)
Table 25 Market by Products (%)
Table 26 Global Healthcare-associated Infections Diagnostics Market by Test Type ($ million)
Table 27 Market by Test Type (%)
Table 28 Global Healthcare-associated Infections Diagnostics Market by Infection Type ($ million)
Table 29 Market by Infection Type (%)
Table 30 Global Healthcare-associated Infections Diagnostics Market by End-user Type ($ million)
Table 31 Market by End-user Type (%)
Table 32 Global Healthcare-associated Infections Diagnostics Market by Geography ($ million)
Table 33 Market by Geography (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
